Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMTX Gemini Therapeutics	$51.68 +0.1%	$47.45	$1.16 ▼ $14.10	$2.24B	-0.12	189,291 shs	288,372 shs
LNTH Lantheus	$80.95 +0.2%	$85.93	$73.11 ▼ $126.89	$5.59B	0.11	1.01 million shs	943,124 shs
ROIV Roivant Sciences	$11.54 +0.3%	$11.03	$8.73 ▼ $13.06	$7.82B	1.16	5.59 million shs	7.28 million shs
TGTX TG Therapeutics	$37.30 +2.0%	$37.11	$16.65 ▼ $46.48	$5.80B	1.94	2.93 million shs	1.67 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMTX Gemini Therapeutics	+0.14%	-0.65%	+9.10%	-2.10%	+14.90%
LNTH Lantheus	+0.17%	+3.89%	+9.60%	-17.76%	+2.53%
ROIV Roivant Sciences	+0.35%	+3.87%	+6.16%	+10.54%	+5.77%
TGTX TG Therapeutics	+2.02%	+6.57%	+7.90%	-8.56%	+102.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	4.2303 of 5 stars	3.5	1.0	0.0	4.2	1.3	2.5	1.9
ROIV Roivant Sciences	2.6194 of 5 stars	3.5	3.0	0.0	0.0	2.4	2.5	0.0
TGTX TG Therapeutics	3.0597 of 5 stars	1.4	1.0	0.0	3.5	2.2	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
LNTH Lantheus	3.00	Buy	$130.50	61.21% Upside
ROIV Roivant Sciences	3.00	Buy	$17.50	51.65% Upside
TGTX TG Therapeutics	2.80	Moderate Buy	$40.80	9.38% Upside

Current Analyst Ratings Breakdown

Latest GMTX, ROIV, LNTH, and TGTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	LNTH Lantheus	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$122.00 ➝ $109.00
6/18/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
5/28/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
5/8/2025	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$127.00 ➝ $117.00
4/21/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
LNTH Lantheus	$1.53B	3.65	$7.11 per share	11.39	$15.65 per share	5.17
ROIV Roivant Sciences	$29.05M	270.05	N/A	N/A	$7.45 per share	1.55
TGTX TG Therapeutics	$329M	18.00	$0.12 per share	304.76	$1.43 per share	26.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
LNTH Lantheus	$312.44M	$3.52	23.00	12.83	N/A	16.55%	36.99%	20.55%	7/30/2025 (Estimated)
ROIV Roivant Sciences	-$171.98M	-$0.25	N/A	N/A	N/A	-225.71%	-14.76%	-13.69%	8/6/2025 (Estimated)
TGTX TG Therapeutics	$23.38M	$0.24	155.42	37.30	N/A	10.13%	18.88%	7.05%	8/5/2025 (Estimated)

Latest GMTX, ROIV, LNTH, and TGTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q4 2025	ROIV Roivant Sciences	-$0.16	-$0.31	-$0.15	-$0.29	$62.17 million	$7.57 million
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million
5/7/2025	Q1 2025	TGTX TG Therapeutics	$0.19	$0.03	-$0.16	$0.03	$117.07 million	$120.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMTX Gemini Therapeutics	N/A	71.49	71.49
LNTH Lantheus	0.49	5.74	5.46
ROIV Roivant Sciences	N/A	33.47	33.47
TGTX TG Therapeutics	1.03	4.02	3.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMTX Gemini Therapeutics	75.42%
LNTH Lantheus	99.06%
ROIV Roivant Sciences	64.76%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
GMTX Gemini Therapeutics	12.90%
LNTH Lantheus	2.00%
ROIV Roivant Sciences	7.90%
TGTX TG Therapeutics	10.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
LNTH Lantheus	700	69.19 million	67.80 million	Optionable
ROIV Roivant Sciences	860	679.81 million	626.10 million	Optionable
TGTX TG Therapeutics	290	158.76 million	141.86 million	Optionable

GMTX, ROIV, LNTH, and TGTX Headlines

Recent News About These Companies

Assenagon Asset Management S.A. Cuts Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

June 20, 2025 | marketbeat.com

Insider Selling: Yann Echelard Unloads $369K Of TG Therapeutics Stock

June 17, 2025 | benzinga.com

Are Options Traders Betting on a Big Move in TG Therapeutics Stock?

June 17, 2025 | msn.com

Yann Echelard Sells 10,000 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) Stock

June 17, 2025 | insidertrades.com

Insider Selling: TG Therapeutics, Inc. (NASDAQ:TGTX) Director Sells 10,000 Shares of Stock

June 16, 2025 | marketbeat.com

Cantor Fitzgerald Estimates TG Therapeutics FY2026 Earnings

June 10, 2025 | marketbeat.com

GAMMA Investing LLC Purchases 176,573 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

June 9, 2025 | marketbeat.com

TG Therapeutics (NasdaqCM:TGTX) Stock Rises 13% In Last Month

June 7, 2025 | uk.finance.yahoo.com

TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

June 6, 2025 | globenewswire.com

Wellington Management Group LLP Trims Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

June 6, 2025 | marketbeat.com

Two Sigma Advisers LP Sells 214,800 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

June 6, 2025 | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Trading Up 6.2% - Still a Buy?

June 5, 2025 | marketbeat.com

Mackenzie Financial Corp Cuts Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

June 5, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

June 1, 2025 | marketbeat.com

NorthCrest Asset Manangement LLC Invests $448,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)

May 31, 2025 | marketbeat.com

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

May 30, 2025 | theglobeandmail.com

Man Group plc Purchases Shares of 9,589 TG Therapeutics, Inc. (NASDAQ:TGTX)

May 29, 2025 | marketbeat.com

TG Therapeutics: Estimates Could Soon Be Raised Again

May 28, 2025 | seekingalpha.com

Bank of America Corp DE Has $6.95 Million Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

May 28, 2025 | marketbeat.com

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

May 27, 2025 | globenewswire.com

Connecticut Wealth Management LLC Sells 13,000 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

May 25, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMTX, ROIV, LNTH, and TGTX Company Descriptions

Gemini Therapeutics NASDAQ:GMTX

$51.68 +0.07 (+0.14%)

As of 06/23/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Lantheus NASDAQ:LNTH

$80.95 +0.14 (+0.17%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$79.31 -1.64 (-2.02%)

As of 04:05 AM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Roivant Sciences NASDAQ:ROIV

$11.54 +0.04 (+0.35%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$11.55 +0.01 (+0.09%)

As of 04:01 AM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

TG Therapeutics NASDAQ:TGTX

$37.30 +0.74 (+2.02%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$37.52 +0.22 (+0.58%)

As of 04:18 AM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time